BioGX: Difference between revisions

From Bhamwiki
Jump to navigation Jump to search
No edit summary
No edit summary
 
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
'''BioGX''' is a molecular diagnostics company with offices in [[Birmingham]]'s [[Innovation Depot]]. The company also operates a second manufacturing and distribution center, BioGX BV, in Amsterdam, the Netherlands.
'''BioGX''' is a molecular diagnostics company headquartered at 2450 [[Valleydale Road]]. The company also operates a second manufacturing and distribution center, BioGX BV, in Amsterdam, the Netherlands.


BioGX was founded in [[2007]] by [[Michael Vickery]]. [[Shazi Iqbal]] has served as CEO since [[2011]]. Both are veterans of the Sunnyvale, California-based Cepheid Inc.
BioGX was founded in [[2007]] by [[Michael Vickery]] and was located in [[Birmingham]]'s [[Innovation Depot]] until purchasing its present 30,000 square-foot building in [[2021]]. [[Shazi Iqbal]] has served as CEO since [[2011]]. Both are veterans of the Sunnyvale, California-based Cepheid Inc.


BioGX partnered with Becton Dickinson & Co. of New Jersey to develop a rapid [[2020 Coronavirus pandemic|COVID-19]] RNA test for its "BD Max" diagnostic platform. The test was granted an emergency use authorization from the U.S. Food and Drug Administration in April 2020. It's "XFree" test process was given the same type of approval in October.
BioGX partnered with Becton Dickinson & Co. of New Jersey to develop a rapid [[2020 Coronavirus pandemic|COVID-19]] RNA test for its "BD Max" diagnostic platform. The test was granted an emergency use authorization from the U.S. Food and Drug Administration in April 2020. It's "XFree" test process was given the same type of approval in October.
Line 9: Line 9:
* Patchen, Tyler (April 6, 2020) "Bham biotech firm's COVID-19 test collaboration gets FDA authorization." {{BBJ}}
* Patchen, Tyler (April 6, 2020) "Bham biotech firm's COVID-19 test collaboration gets FDA authorization." {{BBJ}}
* Patchen, Tyler (October 27, 2020) "Birmingham company secures FDA emergency use authorization for Covid-19 test." {{BBJ}}
* Patchen, Tyler (October 27, 2020) "Birmingham company secures FDA emergency use authorization for Covid-19 test." {{BBJ}}
* Patchen, Tyler (January 26, 2021) "BioGX to move to facility on Valleydale Road." {{BBJ}}
* Thornton, William (February 4, 2021) "BioGX moving to Shelby County, to hire 30." {{BN}}
* Patchen, Tyler (July 1, 2021) "BioGX receives emergency use authorization from FDA for Covid test." {{BBJ}}


==External links==
==External links==

Latest revision as of 16:02, 1 July 2021

BioGX is a molecular diagnostics company headquartered at 2450 Valleydale Road. The company also operates a second manufacturing and distribution center, BioGX BV, in Amsterdam, the Netherlands.

BioGX was founded in 2007 by Michael Vickery and was located in Birmingham's Innovation Depot until purchasing its present 30,000 square-foot building in 2021. Shazi Iqbal has served as CEO since 2011. Both are veterans of the Sunnyvale, California-based Cepheid Inc.

BioGX partnered with Becton Dickinson & Co. of New Jersey to develop a rapid COVID-19 RNA test for its "BD Max" diagnostic platform. The test was granted an emergency use authorization from the U.S. Food and Drug Administration in April 2020. It's "XFree" test process was given the same type of approval in October.

References

External links

Retrieved from "http://bhamwiki.com/w/index.php?title=BioGX&oldid=181507"